CALIXAR’s Multidrug resistance ABC transporter ATP-binding/permease protein BmrA expedites reliable fragment-based drug design (FBDD), structure-based medication discovery (SBDD) and antibody development against this specific target.
Unlike CALIXAR’s BmrA membrane targets, other alternative approaches result in a BmrA membrane protein that becomes mutated and truncated.
As with all transporters, Multidrug resistance ABC transporter ATP-binding/permease protein BmrA is unpredictable targets, difficult to produce natively without particular technology. Traditionally, BmrA membrane proteins were often developed in a solution that naturally could not be pure, nor native (truncated, mutated), and consequently are moderately unstable.
Thanks to CALIXAR’s expertise, we are able to deliver BmrA membrane targets that maintain the structure and function of the target. Our Multidrug resistance ABC transporter ATP-binding/permease protein BmrA is pure, native, unaltered and stable.
CALIXAR has the capacity to provide high quality, native, wild-type, unaltered, unmutated and untruncated targets for antibody development and pharmaceutical discovery projects. We are unparalleled in the market and at the vanguard of Membrane Protein technology.
- Antibodies (including nanobodies, scaffold proteins, aptamers)
- Small molecules
- 3D Structures (classical X-ray or XFEL, Cryo-EM, NMR)
- Drug discovery (Screening: HTS, FBDD, SBDD; Hit and lead validation)
- Antibody discovery (Immunization and display technologies)
- Clinical stage (drug validation on reliable native BmrA)